Form 6-K/A MIZUHO FINANCIAL GROUP For: May 29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2026
Commission File Number 001-33098
Mizuho Financial Group, Inc.
(Translation of registrant’s name into English)
5-5, Otemachi 1-chome
Chiyoda-ku, Tokyo 100-8176
Japan
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
The registrant filed the following documents with the Tokyo Stock Exchange on May 28, 2026 (local time): 1) the Notice of Convocation of FY 2026 Ordinary General Shareholders’ Meeting, and 2) the Business Report for the period from April 1, 2025 to March 31, 2026. The registrant furnished the English translations of such documents on Form 6-K (the “Form 6-K”) on the same day (the U.S. Eastern time). Subsequently, the registrant filed corrected versions of such documents with the Tokyo Stock Exchange on May 29, 2026 (local time) and hereby furnishes the English translations of such corrected versions on this Form 6-K/A to amend and restate the Form 6-K in its entirety.
EXHIBIT INDEX
| Exhibit | Description | |
| 99.1 | Notice of Convocation of FY 2026 Ordinary General Shareholders’ Meeting, and the Business Report for the period from April 1, 2025 to March 31, 2026 (Corrected Version) (English Translation) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: May 29, 2026 | ||
| Mizuho Financial Group, Inc. | ||
| By: |
/s/ Makoto Samejima | |
| Name: |
Makoto Samejima | |
| Title: |
Senior Managing Corporate Executive / Group CFO | |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MicroVision enters agreement to sell up to $42 million in common stock
- Mizuho on BridgeBio Pharma (BBIO): 'We believe that any such potential transient weakness could represent a potential entry point opportunity'
- Enliven Therapeutics launches $250 million public stock offering
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
MizuhoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share